These results strongly suggest that CML cell growth suppression by short-term treatment with DAS-IAP is due to degradation of the BCR-ABL protein and not to ABL kinase inhibition, implying that cell growth inhibition by degradation of BCR-ABL is sustained longer than that by inhibition of BCR-ABL kinase activity. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.